BioVaria 2016

Published: 15-Apr-2016

17 May 2016

Conference

Munich, Germany


Dealmakers and investors from the international biopharmaceutical industry will come together in Munich with Europe’s leading life-science researchers, entrepreneurs and technology transfer professionals to initiate partnerships for the development of high-potential academic projects.

Organiser: Ascenion

www.biovaria.org/programme/technologies/

Trending Articles

  1. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  2. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  3. Pharmapack Europe<font color="red"><sup><i>new dates</i></sup></font> 13–14 October 2021 | Conference | Paris, France
  4. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  5. Lab Innovations 30-31 October 2024 | Exhibition | Birmingham, UK

You may also like

Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Research & Development

Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
Research & Development

Kynos Therapeutics’ KMO inhibitor demonstrates safety and tolerability in Phase I study

The lead drug candidate, KNS366, demonstrated its safety and tolerability in healthy adult participants in a Phase I trial
Subscribe now